Page last updated: 2024-09-04

canertinib and Acute Myelogenous Leukemia

canertinib has been researched along with Acute Myelogenous Leukemia in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Djerf, EA; Hallbeck, AL; Jönsson, JI; Trinks, C; Walz, TM1
Druid, P; Eliasson, P; Gréen, H; Jönsson, JI; Lotfi, K; Nordigården, A; Rönnstrand, L; Trinks, C; Walz, TM; Zetterblad, J1

Other Studies

3 other study(ies) available for canertinib and Acute Myelogenous Leukemia

ArticleYear
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells.
    Biochemical and biophysical research communications, 2010, Feb-26, Volume: 393, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; G1 Phase; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Morpholines; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Receptor, ErbB-2

2010
Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
    British journal of haematology, 2011, Volume: 155, Issue:2

    Topics: Animals; Apoptosis; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred DBA; Morpholines; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Oncogene Proteins v-erbB; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Signal Transduction; Tandem Repeat Sequences; Tumor Cells, Cultured

2011
chemdatabank.com